CDC & FDA Antimicrobial Resistance (AR) Isolate Bank
As of April 1, 2022, the AR Isolate Bank shipped more than 7,000 isolate panels (more than 269,000 isolates). The AR Isolate Bank helps:
- Strengthen diagnostics by validating lab tests
- Inform research and development to
- develop drugs like antibiotics and antifungals
- develop diagnostic devices, tests, or assays
- satisfy a request or support an application to FDA
- Perform testing to ensure drug effectiveness
- Study pathogenic mechanisms and genotypic basis of resistance (the ability of germs to adapt and evolve)
- Detect new and unusual public health resistance threats to rapidly implement recommended infection control measures.
This work ultimately improves patient care and builds solutions against resistance threats.
CDC has one of the largest collections of isolates gathered from national reference labs and tracking activities, taken from specimens in healthcare, food, and the community, like gonorrhea. Isolates are provided at no cost to approved institutions, and customers pay for shipping.
- Samples are assembled based on public health threats
- Isolates are delivered in panels, not piecemeal
- It allows researchers to quickly and easily obtain the specific samples they need
- It reduces obstacles that may keep companies or researchers from engaging in finding resistance solutions
- Samples are accompanied by publicly available data (antimicrobial susceptibility profile and resistance mechanisms) to improve efficiencies
- It offers a convenient web ordering system that increases efficiency
- Confirmatory testing is performed periodically to ensure samples maintain their resistance mechanisms over time
- Panels are refreshed as needed to include susceptibility data for newly approved antibiotics, relevant species or mechanisms, andupdated whole genome sequence analyses
The isolates helped us challenge our diagnostic tests to ensure they can detect a variety of resistance targets,
- The Active Bacterial Core surveillance (ABCs) Isolate Bank includes an extensive collection of isolates: group A Streptococcus, group B Streptococcus, Streptoccocus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. ABCs is a core program within CDC’s Emerging Infections Programs (EIP) network, and is an active laboratory- and population-based surveillance system for invasive bacterial pathogens of public health importance.
- The Antibacterial Resistance Leadership Group (ARLG) Virtual Repository provides researchers with clinically well-characterized gram-positive and gram-negative bacteria.
- BEI Resources was established by the National Institute of Allergy and Infectious Diseases (NIAID) to provide tools and information for studying Category A, B, and C priority pathogens, emerging infectious disease agents, non-pathogenic microbes (germs), and other microbiological materials of relevance (e.g., reagents) to the research community.
- CDC provides downloadable minimum inhibitory concentration (MIC) distributions that perform antimicrobial susceptibility testing (AST) of bacterial and Candida bloodstream isolates. These isolates are tested in compliance with standards established by the Clinical and Laboratory Standards Institute (CLSI).